Our top pick for
Veracyte, Inc is a biotechnology business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 320 staff and has a trailing 12-month revenue of around USD$117.5 million.
|52-week range||USD$13.9 - USD$86.03|
|50-day moving average||USD$63.2215|
|200-day moving average||USD$47.4356|
|Wall St. target price||USD$84.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.288|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$117.5 million|
|Gross profit TTM||USD$77.1 million|
|Return on assets TTM||-5.6%|
|Return on equity TTM||-10.57%|
|Market capitalisation||USD$3.8 billion|
TTM: trailing 12 months
There are currently 2.7 million Veracyte shares held short by investors – that's known as Veracyte's "short interest". This figure is 32.3% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Veracyte shares can be evaluated.
Veracyte's "short interest ratio" (SIR) is the quantity of Veracyte shares currently shorted divided by the average quantity of Veracyte shares traded daily (recently around 1.0 million). Veracyte's SIR currently stands at 2.7. In other words for every 100,000 Veracyte shares traded daily on the market, roughly 2700 shares are currently held short.
However Veracyte's short interest can also be evaluated against the total number of Veracyte shares, or, against the total number of tradable Veracyte shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veracyte's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Veracyte shares in existence, roughly 40 shares are currently held short) or 0.041% of the tradable shares (for every 100,000 tradable Veracyte shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Veracyte.
Find out more about how you can short Veracyte stock.
We're not expecting Veracyte to pay a dividend over the next 12 months.
Over the last 12 months, Veracyte's shares have ranged in value from as little as $13.9 up to $86.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 0.6932. This would suggest that Veracyte's shares are less volatile than average (for this exchange).
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.